Sirolimus for the Prevention of In-Stent Restenosis in a Coronary Artery
- 2 October 2003
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 349 (14) , 1307-1309
- https://doi.org/10.1056/nejmp038141
Abstract
Sirolimus (rapamycin), an inhibitor of in-stent restenosis in the coronary arteries, is having a substantial effect on the care of patients with coronary artery disease, was discovered in a soil sample from Easter Island (known locally as Rapa Nui). A naturally occurring product that is isolated from Streptomyces hygroscopicus, sirolimus is an extremely lipophilic (hydrophobic) macrolide that was initially developed as an antifungal agent on the basis of its ability to inhibit the growth of yeast. However, sirolimus was quickly observed to have potent immunosuppressive activity in mammals, which put a halt to its development as an antibiotic.In 1988, . . .Keywords
This publication has 6 references indexed in Scilit:
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003
- Coronary Restenosis After Sirolimus-Eluting Stent ImplantationCirculation, 2003
- Inhibition of Intimal Thickening After Balloon Angioplasty in Porcine Coronary Arteries by Targeting Regulators of the Cell CycleCirculation, 1999
- Rapamycin Resistance Tied to Defective Regulation of p27Kip1Molecular and Cellular Biology, 1996
- Rapamycin inhibits vascular smooth muscle cell migration.Journal of Clinical Investigation, 1996
- Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle CellsCirculation Research, 1995